With the eye-catching commercial success of new treatments for wet age-related macular degeneration, venture capital investors as well as industry players are turning their attention to the non-exudative form of the disease, dry AMD.
Genentech Inc./Roche has been remarkably successful in wet AMD with its drug Lucentis (ranibizumab), as has Regeneron Inc.’s Eylea (aflibercept),...